{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T21:08:28Z","timestamp":1789679308579,"version":"4.0.1"},"reference-count":27,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2024,4,1]]},"abstract":"\n Importance<\/jats:title>\n Evidence on the bleeding risk associated with low-density lipoprotein cholesterol (LDL-C) levels in patients receiving dual antiplatelet therapy (DAPT) remains sparse.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To investigate the association of LDL-C levels with bleeding risk in patients with minor ischemic stroke (MIS) or high-risk transient ischemic attack (HRTIA) receiving DAPT.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This cohort study was an analysis of pooled data from 2 randomized, double-blind, placebo-controlled clinical trials in China of patients with MIS or HRTIA who were receiving DAPT: the CHANCE (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events) trial enrolled patients at 114 sites from October 2009 to July 2012, and the CHANCE-2 enrolled patients at 202 centers from September 2019 to March 2021. Both sets of patients were followed up for 90 days. Data analysis was performed from August 2022 to May 2023.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Baseline LDL-C levels and receipt of ticagrelor-aspirin and clopidogrel-aspirin DAPT.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcome was any bleeding, and the secondary outcome was severe or moderate bleeding within 3 months after randomization. The association of LDL-C levels and all outcomes was assessed by using the Cox proportional hazard model. Hazard ratios (HRs) with 95% CIs were calculated on univariable (unadjusted) Cox regression models. Adjusted HRs (aHRs) and their 95% CIs were calculated on multivariable Cox regression models.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n In total, 8996 patients with acute MIS or HRTIA who were receiving DAPT were included in the 2 trials, of whom 1066 without serum specimens and 490 patients with missing baseline LDL-C value were excluded. Finally, 7440 patients with DAPT (4486 in the clopidogrel-aspirin group and 2954 in the ticagrelor-aspirin group) were included in this study. The median (IQR) age was 64.32 (56.56-71.30) years, and 2479 patients (33.32%) were women. A total of 270 (3.63%) bleeding events were reported at 3 months, and LDL-C less than 70 mg\/dL was associated with an increased risk of both any bleeding (aHR,\u20091.48; 95% CI,\u20091.03-2.12), and severe or moderate bleeding (aHR,\u20092.78; 95% CI,\u20091.18-6.53). The risk of any bleeding was increased at lower LDL-C levels in the ticagrelor-aspirin group (aHR,\u20091.71; 95% CI,\u20091.08-2.72). However, an increased risk of any bleeding was not observed in the clopidogrel-aspirin group (aHR,\u20091.30; 95% CI,\u20090.73-2.30). There was no significant association between LDL-C levels and the risk of severe or moderate bleeding in either the ticagrelor-aspirin or clopidogrel-aspirin group.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n These findings suggest that low LDL-C levels are associated with an increased bleeding risk within 3 months among patients with MIS or HRTIA receiving DAPT, especially those taking ticagrelor-aspirin. Weighing the risks and benefits is crucial when simultaneously considering the selection of LDL-C target strategies and DAPT regimens among these patients.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamaneurol.2024.0086","type":"journal-article","created":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T11:00:46Z","timestamp":1709550046000},"page":"354","source":"Crossref","is-referenced-by-count":10,"title":["LDL-C Levels and Bleeding Risk in Patients Taking DAPT After Minor Ischemic Stroke or TIA"],"prefix":"10.1001","volume":"81","author":[{"given":"Aichun","family":"Cheng","sequence":"first","affiliation":[{"name":"Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"},{"name":"China National Clinical Research Center for Neurological Diseases, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Xue","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"},{"name":"China National Clinical Research Center for Neurological Diseases, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anxin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"},{"name":"China National Clinical Research Center for Neurological Diseases, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"},{"name":"China National Clinical Research Center for Neurological Diseases, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyuan","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"},{"name":"China National Clinical Research Center for Neurological Diseases, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinxi","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"},{"name":"China National Clinical Research Center for Neurological Diseases, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"},{"name":"China National Clinical Research Center for Neurological Diseases, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"},{"name":"China National Clinical Research Center for Neurological Diseases, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"},{"name":"China National Clinical Research Center for Neurological Diseases, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"},{"name":"China National Clinical Research Center for Neurological Diseases, Beijing, China"},{"name":"Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China"},{"name":"Chinese Institute for Brain Research, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"12","key":"noi240004r1","doi-asserted-by":"publisher","first-page":"3198","DOI":"10.1161\/STROKEAHA.107.493106","article-title":"Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.","volume":"38","author":"Amarenco","year":"2007","journal-title":"Stroke"},{"issue":"1","key":"noi240004r2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa1910355","article-title":"A comparison of two LDL cholesterol targets after ischemic stroke.","volume":"382","author":"Amarenco","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"noi240004r3","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1161\/STR.0b013e318284056a","article-title":"Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association.","volume":"44","author":"Jauch","year":"2013","journal-title":"Stroke"},{"key":"noi240004r4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.atherosclerosis.2020.12.013","article-title":"New cardiovascular prevention guidelines: How to optimally manage dyslipidaemia and cardiovascular risk in 2021 in patients needing secondary prevention?","volume":"319","author":"Atar","year":"2021","journal-title":"Atherosclerosis"},{"issue":"7","key":"noi240004r5","doi-asserted-by":"publisher","first-page":"e364","DOI":"10.1161\/STR.0000000000000375","article-title":"2021 Guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association\/American Stroke Association.","volume":"52","author":"Kleindorfer","year":"2021","journal-title":"Stroke"},{"issue":"18","key":"noi240004r6","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease.","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"issue":"25","key":"noi240004r7","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes.","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"issue":"3","key":"noi240004r8","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1093\/eurheartj\/ehn586","article-title":"Profile of bleeding and ischaemic complications with bivalirudin and unfractionated heparin after percutaneous coronary intervention.","volume":"30","author":"Iijima","year":"2009","journal-title":"Eur Heart J"},{"issue":"33","key":"noi240004r9","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.1093\/eurheartj\/ehab418","article-title":"LDL cholesterol levels and in-hospital bleeding in patients on high-intensity antithrombotic therapy: findings from the CCC-ACS project.","volume":"42","author":"Yang","year":"2021","journal-title":"Eur Heart J"},{"issue":"2","key":"noi240004r10","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1136\/svn-2022-001612","article-title":"Low LDL-C level and intracranial haemorrhage risk after ischaemic stroke: a prospective cohort study.","volume":"8","author":"Xu","year":"2023","journal-title":"Stroke Vasc Neurol"},{"issue":"4","key":"noi240004r11","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/s41591-019-0366-x","article-title":"Causal associations of blood lipids with risk of ischemic stroke and intracerebral hemorrhage in Chinese adults.","volume":"25","author":"Sun","year":"2019","journal-title":"Nat Med"},{"issue":"1","key":"noi240004r12","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1161\/CIRCULATIONAHA.120.046290","article-title":"PCSK9 (proprotein convertase subtilisin\/kexin 9) enhances platelet activation, thrombosis, and myocardial infarct expansion by binding to platelet CD36.","volume":"143","author":"Qi","year":"2021","journal-title":"Circulation"},{"issue":"1","key":"noi240004r13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1215340","article-title":"Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"issue":"3","key":"noi240004r14","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1056\/NEJMoa1800410","article-title":"Clopidogrel and aspirin in acute ischemic stroke and high-Risk TIA.","volume":"379","author":"Johnston","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"noi240004r15","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1056\/NEJMoa1916870","article-title":"Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA.","volume":"383","author":"Johnston","year":"2020","journal-title":"N Engl J Med"},{"issue":"27","key":"noi240004r16","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1056\/NEJMoa2111749","article-title":"Ticagrelor versus clopidogrel in CYP2C19 loss-of-function carriers with stroke or TIA.","volume":"385","author":"Wang","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"noi240004r17","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1002\/ana.v91.3","article-title":"Bleeding risk of dual antiplatelet therapy after minor stroke or transient ischemic attack.","volume":"91","author":"Wang","year":"2022","journal-title":"Ann Neurol"},{"key":"noi240004r18","doi-asserted-by":"publisher","first-page":"l2211","DOI":"10.1136\/bmj.l2211","article-title":"Ticagrelor plus aspirin versus clopidogrel plus aspirin for platelet reactivity in patients with minor stroke or transient ischaemic attack: open label, blinded endpoint, randomised controlled phase II trial.","volume":"365","author":"Wang","year":"2019","journal-title":"BMJ"},{"issue":"11","key":"noi240004r19","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes.","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"issue":"2","key":"noi240004r20","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1161\/CIRCULATIONAHA.120.046786","article-title":"Comparative efficacy and safety of oral P2Y12 inhibitors in acute coronary syndrome: network meta-analysis of 52 816 patients from 12 randomized trials.","volume":"142","author":"Navarese","year":"2020","journal-title":"Circulation"},{"issue":"2","key":"noi240004r21","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1136\/svn-2021-000874","article-title":"Analytical validation of GMEX rapid point-of-care CYP2C19 genotyping system for the CHANCE-2 trial.","volume":"6","author":"Meng","year":"2021","journal-title":"Stroke Vasc Neurol"},{"issue":"1","key":"noi240004r22","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1001\/jama.2016.8662","article-title":"Association between CYP2C19 loss-of-function allele status and efficacy of clopidogrel for risk reduction among patients with minor stroke or transient ischemic attack.","volume":"316","author":"Wang","year":"2016","journal-title":"JAMA"},{"issue":"10","key":"noi240004r23","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1056\/NEJM199309023291001","article-title":"An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction.","volume":"329","author":"GUSTO Investigators","year":"1993","journal-title":"N Engl J Med"},{"issue":"12","key":"noi240004r24","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1001\/jamaneurol.2019.2531","article-title":"Outcomes associated with clopidogrel-aspirin use in minor stroke or transient ischemic attack: a pooled analysis of Clopidogrel in High-Risk Patients With Acute Non-Disabling Cerebrovascular Events (CHANCE) and Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trials.","volume":"76","author":"Pan","year":"2019","journal-title":"JAMA Neurol"},{"key":"noi240004r25","doi-asserted-by":"publisher","first-page":"k5108","DOI":"10.1136\/bmj.k5108","article-title":"Clopidogrel plus aspirin versus aspirin alone for acute minor ischaemic stroke or high risk transient ischaemic attack: systematic review and meta-analysis.","volume":"363","author":"Hao","year":"2018","journal-title":"BMJ"},{"issue":"19","key":"noi240004r26","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1016\/j.jacc.2007.07.058","article-title":"Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.","volume":"50","author":"Storey","year":"2007","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"noi240004r27","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1055\/s-0040-1718729","article-title":"The East Asian paradox: an updated position statement on the challenges to the current antithrombotic strategy in patients with cardiovascular disease.","volume":"121","author":"Kim","year":"2021","journal-title":"Thromb Haemost"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2815831\/jamaneurology_cheng_2024_oi_240004_1711137422.99347.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T11:01:37Z","timestamp":1712574097000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2815831"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,1]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2024.0086","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4,1]]}}}